In our cohort, among the patients that had interstitial lung disease (ILD) associated with CDK4/6 inhibitors, 60% of patients had lung metastases, 50% had a history of chest radiation, and 20% had known pulmonary comorbidities. The gene discussed is CDK4; the disease is interstitial lung disease.